Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Value of Digital Patient Reported Outcomes (PROs) - Long-Term Management of Treatment Fatigue in Relapsed or Refractory Multiple Myeloma

Noa Biran, MD, Emre Yucel, PhD MSc, MBA, BSPharm, Robin Anthony Kouyaté, PhD, Gillian McGovern, MPH, Antoinette Schoenthaler, EdD, Olivia Durling, BS, Rashmi Unawane, MBBS, Andrew Schutt, MSc, Sumeet Panjabi, PhD

Blood (2019) 134 (Supplement_1): 3439.

https://doi.org/10.1182/blood-2019-123154

Published: 2019

Journal Articles

Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US

Rafael Fonseca, MD, May Hagiwara, PhD, Sumeet Panjabi, PhD, Emre Yucel, PhD MSc, MBA, BSPharm, Jacqueline Buchanan, Thomas Delea, MBA

Blood (2019) 134 (Supplement_1): 2211.

https://doi.org/10.1182/blood-2019-123743

Published: 2019

Journal Articles

Could Patients with Multiple Myeloma (MM) Derive Additional Benefit from Their Treatments? Real-World Evidence for Carfilzomib Dosing Intensity on Survival and Treatment Progression

Rohan Medhekar, PhD, Dionne Hines, MPH, PhD, Sumeet Panjabi, PhD, Tim Welliver, MD PhD, Xin Wang, PhD, Rolin L. Wade, RPh, MS

Blood (2018) 132 (Supplement 1): 836.

https://doi.org/10.1182/blood-2018-99-113414

Published: 2018

Journal Articles

Burden of Disease Progression in Patients with Multiple Myeloma Who Have Received at Least One Line of Therapy in the US

May Hagiwara, PhD, Thomas Delea, MBA, MSIA, Sumeet Panjabi, PhD, Emre Yucel, PhD MSc, MBA, BSPharm, Rafael Fonseca, MD

Blood (2018) 132 (Supplement 1): 4754.

https://doi.org/10.1182/blood-2018-99-117230

Published: 2018

Journal Articles

A Mixed Methods Approach to Generate Meaningful Change Estimates for the EORTC QLQ-MY20

Emre Yucel, PhD MSc, MBA, BSPharm, Andrew Trigg, MSc, Kate Sully, PhD, Amelia Harper, Nicola Bonner, MSc, Nina Shah, MD, Sumeet Panjabi, PhD, Kim Cocks

Blood (2018) 132 (Supplement 1): 5912.

https://doi.org/10.1182/blood-2018-99-116746

Published: 2018

Journal Articles

Economic Burden of Stem Cell Transplant Among Patients with Multiple Myeloma

Sikander Ailawadhi, Sumeet Panjabi, PhD, Nicole Princic, MS, Rob Fowler, MS, Oth Tran, MA, Francesca Gatta, MSc, BSc, Rohan Medhekar, PhD

Blood (2017) 130 (Supplement 1): 3427.

https://doi.org/10.1182/blood.V130.Suppl_1.3427.3427

Published: 2017

Journal Articles

Carfilzomib Dosing Patterns and Time to Next Treatment Among Adult Patients with Multiple Myeloma Treated in the US Community Oncology Setting

Robert M Rifkin, MD, E Susan Amirian, PhD MS, Rohan Medhekar, PhD, Thomas Wilson, PhD DrPH, Marley Boyd, MS, Khalid Mezzi, MD MBA, Sumeet Panjabi, PhD

Blood (2017) 130 (Supplement 1): 3433.

https://doi.org/10.1182/blood.V130.Suppl_1.3433.3433

Published: 2017

Journal Articles

A Real-World Comparative Analysis of Carfilzomib and Other Systemic Multiple Myeloma Chemotherapies in the US Community Oncology Setting

Robert M Rifkin, MD, Rohan Medhekar, PhD, E Susan Amirian, PhD MS, Thomas Wilson, PhD DrPH, Marley Boyd, MS, Khalid Mezzi, MD MBA, Sumeet Panjabi, PhD

Blood (2017) 130 (Supplement 1): 3434.

https://doi.org/10.1182/blood.V130.Suppl_1.3434.3434

Published: 2017

Journal Articles

Costs Associated with Treatment Induced Peripheral Neuropathy in Patients with Multiple Myeloma By Lines of Therapy

Sumeet Panjabi, PhD, Xue Song, PhD, Kathleen Wilson, Jerry Kagan

Blood (2016) 128 (22): 4781.

https://doi.org/10.1182/blood.V128.22.4781.4781

Published: 2016

Journal Articles

Healthcare Utilization (HRU) and Costs Among Multiple Myeloma (MM) Patients (Pts) Receiving Second or Subsequent Line Treatment (Tx) with Carfilzomib (CAR) or Pomalidomide (POM)

Sumeet Panjabi, PhD, May Hagiwara, PhD, Thomas E. Delea, MSIA

Blood (2016) 128 (22): 2419.

https://doi.org/10.1182/blood.V128.22.2419.2419

Published: 2016

Journal Articles

Association Of Treatment Induced Peripheral Neuropathy (TIPN) With Treatment Patterns and Outcomes In Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM)

Thomas G. Martin, III, MD, Sumeet Panjabi, PhD, Jiandong Kerr, MSc, Michael G. Martin, MD, Mark S. Walker, PhD

Blood (2013) 122 (21): 1750.

https://doi.org/10.1182/blood.V122.21.1750.1750

Published: 2013

NARROW

Value of Digital Patient Reported Outcomes (PROs) - Long-Term Management of Treatment Fatigue in Relapsed or Refractory Multiple Myeloma

Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US

Could Patients with Multiple Myeloma (MM) Derive Additional Benefit from Their Treatments? Real-World Evidence for Carfilzomib Dosing Intensity on Survival and Treatment Progression

Burden of Disease Progression in Patients with Multiple Myeloma Who Have Received at Least One Line of Therapy in the US

A Mixed Methods Approach to Generate Meaningful Change Estimates for the EORTC QLQ-MY20

Economic Burden of Stem Cell Transplant Among Patients with Multiple Myeloma

Carfilzomib Dosing Patterns and Time to Next Treatment Among Adult Patients with Multiple Myeloma Treated in the US Community Oncology Setting

A Real-World Comparative Analysis of Carfilzomib and Other Systemic Multiple Myeloma Chemotherapies in the US Community Oncology Setting

Costs Associated with Treatment Induced Peripheral Neuropathy in Patients with Multiple Myeloma By Lines of Therapy

Healthcare Utilization (HRU) and Costs Among Multiple Myeloma (MM) Patients (Pts) Receiving Second or Subsequent Line Treatment (Tx) with Carfilzomib (CAR) or Pomalidomide (POM)

Association Of Treatment Induced Peripheral Neuropathy (TIPN) With Treatment Patterns and Outcomes In Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only